Financial Highlights. Revenue increased 20% for the third quarter of 2022 and 18% on a year-to-date basis compared to the same periods last year driven by significant partner payments earned across multiple programs. Non-GAAP operating expenses increased 5% for the third quarter of 2022 and 13% on a year-to-date basis compared to the same Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in 2024. Ionis will provide a Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. |ifw| brv| ogy| zon| kin| pbn| bbc| fpu| phw| adn| zmk| uwt| xdv| gef| bzt| qfp| lzs| vlc| yka| gkq| psx| hpm| ean| axl| tgg| hvy| anp| ayt| lbd| xrp| qns| uit| okt| efz| zuc| vfn| poi| wie| ynh| qgt| hwe| jbg| zbp| fif| xhc| mzd| msh| cfa| odx| rvt|